Results of EGFR alteration in cohort C subjects baseline ctDNA samples using Amoy 10 gene NGS assay by the central laboratory will be used for publication at the American Society of Clinical Oncology (ASCO) in 2024.
| Title | Results of EGFR alteration in cohort C subjects baseline ctDNA samples using Amoy 10 gene NGS assay by the central laboratory will be used for publication at the American Society of Clinical Oncology (ASCO) in 2024. |
|---|---|
| Description | Amivantamab (ami) is an EGFR-MET bispecific antibody with immune-cell directing activity. Lazertinib (laz) is a CNS-penetrant, 3rd-generation EGFR TKI. Cohort C of the CHRYSALIS-2 study (NCT04077463) enrolled pts with advanced NSCLC harboring atypical non-Ex20ins EGFR mutations who were treatment-naive or had less than or equal to 2 prior lines, which may include a 1st/2nd-generation EGFR TKI (Pts with Ex19del or L858R co-mutations were excluded). This combination was evaluated among pts with atypical EGFR-mutated advanced NSCLC in cohort C.As of 4 Dec 2023, 105 pts received ami+laz, with a median follow-up of 13.8 mo (range, 0.1 - 30.2), and ORR was 51% (95% CI, 41 - 61). To explore whether different EGFR mutations correlate with treatment outcomes, we collected baseline plasma samples and evaluated the EGFR mutation sites using Amoy 10 genes NGS assay. We observed the most common mutations were G719X (54%), L861Q (24%), and S768I (22%). |
| Organism | Homo sapiens |
| Data Type | Expression Profiling by NGS |
| Data Accessibility | Open-access |
| BioProject | PRJCA024371 |
| Release Date | 2024-03-21 |
| Submitter | yongsheng wang (wysdoc756@163.com) |
| Organization | West China Hospital of Stomatology, Sichuan University |
| Submission Date | 2024-03-21 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX006044-01 | amodyx_testing_nsc1001_chn CCO Jan2024 HGR_V3 | 29 | Expression Profiling by NGS | 69.5 KB | xlsx | 0 |